Rallybio's Avenzo Merger Proxy Updated: $215M Financing, $82.2M Net Cash, CFO Transition
RLYB has more than doubled off its 52-week low of $3.67.
Summary
Rallybio's amended S-4 updates the Avenzo reverse merger with a $215M concurrent financing, $82.2M net cash, and CFO transition to part-time status. Stockholder vote set for Q4 2026.
Key Events · M&A and Partnerships · RLYB
-
Concurrent Financing Upsized to $215M
Avenzo's subscription agreement now provides for $215.0 million in aggregate purchase price, up from $200 million in prior filings, with investors expected to own 40.6% of the combined company.
-
Rallybio Net Cash Declines to $82.2M
Rallybio Net Cash was approximately $82.2 million as of August 15, 2026, down from $92.9 million as of June 30, 2026, reflecting continued losses primarily related to the proposed merger.
-
CFO Jonathan Lieber Transitions to Part-Time
Effective September 15, 2026, CFO Jonathan Lieber moves to part-time status with a $420,000 base salary and no annual bonus, with employment terminating upon merger closing.
-
Record Date Set for Stockholder Vote
September 11, 2026 is the record date, with 5,312,584 shares of Rallybio Common Stock outstanding and entitled to vote on the merger proposals.
Analysis · RLYB · Life Sciences
This Amendment No. 2 to the S-4 registration statement updates the pending reverse merger with Avenzo Therapeutics with several material changes. The Concurrent Financing has been upsized to $215 million from $200 million, Rallybio's net cash position has declined to $82.2 million as of August 15, 2026, and CFO Jonathan Lieber has transitioned to part-time status effective September 15, 2026. The record date for the stockholder vote is set for September 11, 2026, with 5,312,584 shares outstanding. Existing Rallybio stockholders will own only 2.8% of the combined company post-merger, while Avenzo equityholders will own 56.6% and Concurrent Financing investors 40.6%. The merger is expected to close in Q4 2026, subject to stockholder approval of the Nasdaq Stock Issuance, Reverse Stock Split, and Name Change proposals.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 383 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $17.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.4M. The 52-week trading range was $3.67 to $17.57. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.